Despite nine AOMs being currently approved for the treatment of obesity, limited clinical trial evidence in older adults predominantly focuses on incretin therapy with glucagon-like peptide-1 receptor agonists (liraglutide, semaglutide, and tirzepatide)
Eur J Clin Nutr 2005, 59: 768-775
Allergic Reactions Some patients taking insulin therapy, including TOUJEO have experienced erythema, local edema, and pruritus at the site of injection
Do not leave on the skin for more than 10 seconds
Innovation in Dual and Triple Agonist Therapies The fact that Cagrilintide and Semaglutide work well together supports the dual-agonist approach and encourages the creation of molecules that combine multiple receptor functions within a single peptide structure
Biochim Biophys Acta 2014;1842:2367-2377